Diplomat Pharmacy — Q4 2018 Earnings Presentation
18 slides from Diplomat Pharmacy's earnings presentation, Mar 15, 2019
Slide 1: Non-GAAP Information and Forward-Looking Statements
NON-GAAP INFORMATION We define Adjusted EBITDA as net income (loss) attributable to Diplomat before interest expense, income taxes, depreciation and amortization, share-based compensation, change in fair value of contingent consideration and other merger and acquisition-related expenses, restructuri
Slide 2: Disclaimer
DIPLOMAT AA Disclaimer NON-GAAP INFORMATION We define Adusted EBITDA as not income (loss) atnbutble to Diplomat betes interest expense, income taxes. epreciabon and amorizaton, shae-based compensation, change inf valuo af coringet consdaraion and ether ‘merer and acquiston‘elated expenses, restructu
Slide 3: 4Q and Full-Year 2018 Highlights
4Q and Full-Year 2018 Highlights 4 Revenue: +18% to $1.4B Adjusted EBITDA1: +63% to $43M Revenue: +22% to $5.5B Adjusted EBITDA1: +65% to $168M 1. A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss) attributable to Diplomat, as prepared in accordance with GAAP can be found
Slide 4: 2018 Accomplishments
I • • • • • • • • • Made significant investments in building a world-class Specialty sales force. Opened a new state of the art high-efficiency dispensing and patient call center in Chandler, AZ. Began implementation of ScriptMed, a new end-to-end specialty pharmacy operating platform. Launched new
Slide 5: 2018 Accomplishments
DIPLOMAT AA 2018 Accomplishments °¢ — Made significant investments in building a world-class Specialty sales force. * Opened a new state of the art high-efficiency dispensing and patient call center in Chandler, AZ. *¢ Began implementation of ScriptMed, a new end-to-end specialty pharmacy operating
Slide 6: Putting Patients First
I D I P L OMAr A Putting Patients First
Slide 7: Diplomat, Putting Patients First
DIPLOMAT, Putting Patients First Infrastructure Employees Specialty Pharmacy Solutions Manufacturer i Infusion Services Innovation vacaut DIPLOMAT PATIENT
Slide 8: 4Q 2018 Financial Results Summary
4Q 2018 Financial Results Summary 9 Revenue: $1.2B Adjusted EBITDA1: $27M GAAP Net Income :$7M GAAP EPS: $0.09 Revenue: $1.4B Adjusted EBITDA1: $43M GAAP Net Loss2:($298M) GAAP EPS2:($4.00) 4Q17 4Q18 1.A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss) attributable to Dipl
Slide 9: 4Q 2018 Segment Details
I PBM Specialty Revenue: $1.28 Net Sales/Rx: $5,184 Revenue: $0.28 Rx volume*: 1,936,000 Gross margin: 5.7% Gross profit/Rx: $294 Gross margin: 14.3% Gross profit/Rx: $13 Rxvolume: 229,000 • Adjusted to 30-day equivalent, where a 90-day prescription is counted as three 30-day prescriptions filled. 1
Slide 10: Full-Year 2018 Financial Results Summary
Full-Year 2018 Financial Results Summary 11 Revenue: $4.5B Adjusted EBITDA1: $102M GAAP Net Income :$15.5M GAAP EPS: $0.23 Cash Flow from Operations: $135M Year-End Net Debt: $666M Revenue: $5.5B Adjusted EBITDA1: $168M GAAP Net loss2:($302M) GAAP EPS2: ($4.07) Cash Flow from Operations: $35M Year-E
Slide 11: Full-Year 2018 Segment Details
I PBM Specialty Revenue: $4.88 Net Sales/Rx: $5,201 Revenue: $0.78 Rx volume*: 8,171,000 Gross margin: 5.9% Gross profit/Rx: $301 Gross margin: 13.1% Gross profit/Rx: $12 Rxvolume: 918,000 *Adjusted to 30-day equivalent, where a 90-day prescription is counted as three 30-day prescriptions filled. 12
Slide 12: Revised 2019 Full-Year Outlook
Revised 2019 Full-Year Outlook 13 1. A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net income (loss) attributable to Diplomat, as prepared in accordance with GAAP can be found in the Appendix to this presentation. $4.4B–$4.6B $300M–$400M $4.7B–$5.0B Specialty Revenue PBM Revenue Total
Slide 13: Updated 2019 Key Headwinds and Tailwinds
Headwinds Payer Reimbursement Pressure Tailwinds New Specialty & PBM Awards Narrowing of Specialty Pharmacy Networks Data & Analytics Monetization Specialty Pharmacy Member Channel Management Uptake of New and Existing Generics and Biosimilars New Indications for Existing Products PBM Contract Losse
Slide 14: Updated 2019 Key Headwinds and Tailwinds
DIPLOMAT Updated 2019 Key Headwinds and Tailwinds Headwinds Payer Reimbursement Pressure Narrowing of Specialty Pharmacy Networks Specialty Pharmacy Member Channel Management PBM Contract Losses PBM Contract Renewal Repricing Moderating Brand Inflation Near-Term Cost of Growth Investments Tailwinds
Slide 15: Reconciliation of Net (Loss) Income to Adjusted EBITDA
I Attributable For the three months ended December 31, For the year ended December 31, 2018 2017 2018 2017 (dollars in thousands) (unaudited) Net (loss) income attributable to Diplomat Pharmacy, Inc. Depreciation and amortization Interest expense Income tax (benefit) expense EBITDA $ (298,025) 24,56
Slide 16: 2019 Full-Year Guidance: GAAP to Non-GAAP Reconciliation
2019 Full-Year Guidance: GAAP to Non-GAAP Reconciliation 1. Assumes a tax rate of (21) and (18) percent, for the low- and high-end, respectively. 17 DIPLOMAT'" I Reconciliation of GAAP to Adjusted EBITDA (dolliars in thousands) (unaudited) Range Net (loss) income attributabr.e to Dipr.omat Pharm acy
Slide 17: Full Year 2018 Supplemental Information
I Full Year 2018 Supplemental Information1 (dollars in millions) (unaudited) For the Twelve Months Ended December 31, 2018 $ $ Amortiza tion of acquisition-related intangible assets, including capitalized software Contingent consideration and other merger and acquisition expense 77.7 6.8 1. The stat
Slide 18: Supplemental Information
DIPLOMAT AA Supplemental Information Full Year 2018 Supplemental Information’ (dollars in millions) (unaudited) For the Twelve Months Ended December 31, 2018 Amortization of acquisition-related intangible assets, including capitalized software $ 777 Contingent consideration and other merger and acqu